← All trials
NCT06417853
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- May 16, 2024
- Last posted
- Aug 22, 2024
- Enrollment
- 258
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vaxxas Pty LtdLead sponsor
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.